Overview Dividends

(TEVA) Teva Pharma Industries - Ratings and Ratios

Exchange: NYSE • Country: Israel • Currency: USD • Type: Common Stock • ISIN: US8816242098

Generic Drugs, CNS Therapies, Respiratory Inhalers, Oncology Injections, OTC Creams

TEVA EPS (Earnings per Share)

EPS Growth (3Y CAGR): 3.48%
EPS Trend (3Y Correlation): -3.2%

TEVA Revenue

Revenue Growth (3Y CAGR): 5.33%
Revenue Trend (3Y Correlation): 61.7%

Description: TEVA Teva Pharma Industries October 14, 2025

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a global generic-drug leader that also markets a range of branded specialty medicines. Its product slate spans tablets, capsules, injectables, inhalers, transdermal patches, and combination devices, with a strategic focus on central nervous system, respiratory, and oncology therapies. In addition to manufacturing active pharmaceutical ingredients (APIs) and offering contract-manufacturing services, Teva runs an out-licensing platform that monetizes its extensive product portfolio.

Key branded assets include COPAXONE for multiple sclerosis, AJOVY (migraine prevention), UZEDY (schizophrenia), and oncology injectables BENDEKA and TREANDA. The company also sells OTC products under brands such as SUDOCREM and FLEGAMINA, and maintains collaborations with partners like Sanofi, Alvotech, and MedinCell to augment its pipeline and distribution reach.

As of FY 2023, Teva reported revenue of roughly $13.5 billion, with a net debt-to-EBITDA ratio of ≈ 3.2, reflecting ongoing balance-sheet deleveraging. The generic market is pressured by US pricing reforms and biosimilar competition, but growth in specialty injectables and the CNS segment offers a higher-margin offset. Assuming the company can sustain its 2024-2025 pipeline launches and maintain cost-discipline, the upside potential hinges on market share gains in the respiratory inhaler space and successful commercialization of its oncology injectables. For a deeper quantitative assessment, you may find the analytics on ValueRay useful for benchmarking TEVA’s valuation against sector peers.

TEVA Stock Overview

Market Cap in USD	27,500m
Sub-Industry	Pharmaceuticals
IPO / Inception	1990-03-26

TEVA Stock Ratings

Growth Rating	61.3%
Fundamental	46.8%
Dividend Rating	18.1%
Return 12m vs S&P 500	21.7%
Analyst Rating	4.45 of 5

TEVA Dividends

Currently no dividends paid

TEVA Growth Ratios

Growth Correlation 3m	80.2%
Growth Correlation 12m	18.6%
Growth Correlation 5y	63.1%
CAGR 5y	36.63%
CAGR/Max DD 3y (Calmar Ratio)	0.84
CAGR/Mean DD 3y (Pain Ratio)	2.53
Sharpe Ratio 12m	-0.08
Alpha	14.05
Beta	0.697
Volatility	38.56%
Current Volume	13106.5k
Average Volume 20d	8653.1k
Stop Loss	23.2 (-3.2%)
Signal	0.22

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (712.0m TTM) > 0 and > 6% of Revenue (6% = 1.01b TTM)

FCFTA 0.01 (>2.0%) and ΔFCFTA -3.29pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 7.42% (prev -8.84%; Δ 16.26pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.03 (>3.0%) and CFO 1.07b > Net Income 712.0m (YES >=105%, WARN >=100%)

Net Debt (14.87b) to EBITDA (2.56b) ratio: 5.80 <= 3.0 (WARN <= 3.5)

Current Ratio 1.11 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (1.16b) change vs 12m ago 2.74% (target <= -2.0% for YES)

Gross Margin 50.09% (prev 49.88%; Δ 0.21pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 41.11% (prev 40.19%; Δ 0.92pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 0.72 (EBITDA TTM 2.56b / Interest Expense TTM 1.28b) >= 6 (WARN >= 3)

Altman Z'' -1.84

(A) 0.03 = (Total Current Assets 12.74b - Total Current Liabilities 11.49b) / Total Assets 39.86b

(B) -0.36 = Retained Earnings (Balance) -14.24b / Total Assets 39.86b

(D) -0.98 = Book Value of Equity -20.79b / Total Liabilities 21.11b

Total Rating: -1.84 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 46.79

1. Piotroski 1.0pt = -4.0

2. FCF Yield 1.36% = 0.68

3. FCF Margin 3.45% = 0.86

4. Debt/Equity 2.35 = 0.23

5. Debt/Ebitda 5.80 = -2.50

6. ROIC - WACC (= -3.10)% = -3.87

7. RoE 11.07% = 0.92

8. Rev. Trend 61.66% = 4.62

9. EPS Trend -3.15% = -0.16

What is the price of TEVA shares?

As of November 10, 2025, the stock is trading at USD 23.97 with a total of 13,106,500 shares traded.
Over the past week, the price has changed by +16.81%, over one month by +19.61%, over three months by +45.98% and over the past year by +38.00%.

Is Teva Pharma Industries a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Teva Pharma Industries (NYSE:TEVA) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 46.79 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TEVA is around 26.42 USD . This means that TEVA is currently undervalued and has a potential upside of +10.22% (Margin of Safety).

Is TEVA a buy, sell or hold?

Teva Pharma Industries has received a consensus analysts rating of 4.45. Therefore, it is recommended to buy TEVA.

Strong Buy: 6
Buy: 4
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the TEVA price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	27.5	14.5%
Analysts Target Price	27.5	14.5%
ValueRay Target Price	28.7	19.9%

TEVA Fundamental Data Overview November 10, 2025

Market Cap USD = 27.50b (27.50b USD * 1.0 USD.USD)
P/E Trailing = 39.2951
P/E Forward = 7.0621
P/S = 1.66
P/B = 3.369
P/EG = 1.2934
Beta = 0.697
Revenue TTM = 16.78b USD
EBIT TTM = 917.0m USD
EBITDA TTM = 2.56b USD
Long Term Debt = 16.00b USD (from longTermDebt, last fiscal year)
Short Term Debt = 24.0m USD (from shortTermDebt, last quarter)
Debt = 17.07b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 14.87b USD (from netDebt column, last quarter)
Enterprise Value = 42.37b USD (27.50b + Debt 17.07b - CCE 2.20b)
Interest Coverage Ratio = 0.72 (Ebit TTM 917.0m / Interest Expense TTM 1.28b)
FCF Yield = 1.36% (FCF TTM 578.0m / Enterprise Value 42.37b)
FCF Margin = 3.45% (FCF TTM 578.0m / Revenue TTM 16.78b)
Net Margin = 4.24% (Net Income TTM 712.0m / Revenue TTM 16.78b)
Gross Margin = 50.09% ((Revenue TTM 16.78b - Cost of Revenue TTM 8.37b) / Revenue TTM)
Gross Margin QoQ = 51.43% (prev 50.34%)
Tobins Q-Ratio = 1.06 (Enterprise Value 42.37b / Total Assets 39.86b)
Interest Expense / Debt = 1.69% (Interest Expense 288.9m / Debt 17.07b)
Taxrate = 32.97% (213.0m / 646.0m)
NOPAT = 614.6m (EBIT 917.0m * (1 - 32.97%))
Current Ratio = 1.11 (Total Current Assets 12.74b / Total Current Liabilities 11.49b)
Debt / Equity = 2.35 (Debt 17.07b / totalStockholderEquity, last quarter 7.25b)
Debt / EBITDA = 5.80 (Net Debt 14.87b / EBITDA 2.56b)
Debt / FCF = 25.73 (Net Debt 14.87b / FCF TTM 578.0m)
Total Stockholder Equity = 6.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.79% (Net Income 712.0m / Total Assets 39.86b)
RoE = 11.07% (Net Income TTM 712.0m / Total Stockholder Equity 6.43b)
RoCE = 4.09% (EBIT 917.0m / Capital Employed (Equity 6.43b + L.T.Debt 16.00b))
RoIC = 2.63% (NOPAT 614.6m / Invested Capital 23.37b)
WACC = 5.73% (E(27.50b)/V(44.57b) * Re(8.58%) + D(17.07b)/V(44.57b) * Rd(1.69%) * (1-Tc(0.33)))
Discount Rate = 8.58% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.18%
[DCF Debug] Terminal Value 79.16% ; FCFE base≈1.14b ; Y1≈1.35b ; Y5≈2.11b
Fair Price DCF = 28.45 (DCF Value 32.64b / Shares Outstanding 1.15b; 5y FCF grow 19.98% → 3.0% )
EPS Correlation: -3.15 | EPS CAGR: 3.48% | SUE: 0.28 | # QB: 0
Revenue Correlation: 61.66 | Revenue CAGR: 5.33% | SUE: 0.81 | # QB: 0

Additional Sources for TEVA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle